Pharvaris (NASDAQ:PHVS) Announces Earnings Results

Pharvaris (NASDAQ:PHVS) announced its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.04, Zacks reports.

Pharvaris Trading Down 1.6%

Shares of NASDAQ PHVS traded down $0.55 during trading hours on Friday, reaching $33.28. The stock had a trading volume of 92,625 shares, compared to its average volume of 452,374. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -10.91 and a beta of -2.48. Pharvaris has a fifty-two week low of $23.01 and a fifty-two week high of $43.25. The firm has a 50-day moving average of $33.29 and a 200-day moving average of $31.29.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PHVS. Citizens Jmp raised their target price on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday, September 9th. Oppenheimer reaffirmed an “outperform” rating on shares of Pharvaris in a report on Friday, October 23rd. Wedbush increased their price target on shares of Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, October 15th. Finally, Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.53.

Insider Activity

In other Pharvaris news, insider Wim Souverijns sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $39.31, for a total value of $786,200.00. Following the completion of the sale, the insider owned 45,111 shares in the company, valued at approximately $1,773,313.41. The trade was a 30.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elisabeth Bjork sold 52,500 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the sale, the director directly owned 15,167 shares of the company’s stock, valued at $574,677.63. The trade was a 77.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 510,810 shares of company stock worth $18,563,973 over the last ninety days. 11.84% of the stock is owned by corporate insiders.

About Pharvaris

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.